Empagliflozin
Empagliflozin 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Obesity、Vascular Health。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
10 项
已进入 III/IV 期
20 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- VA Office of Research and Development
- Huashan Hospital
- University of Texas Southwestern Medical Center
- Mayo Clinic
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
- Hotel Dieu de France Hospital
- Vanderbilt University Medical Center
- Fazaia Ruth Pfau Medical College
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
中国、美国、Russia、Lebanon、Pakistan、Slovenia、Egypt、德国、法国、意大利、瑞士、Greece
正在招募患者的 Empagliflozin 研究
SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism
II 期招募中中国NCT07482020Polypill for Prevention of Cardiomyopathy
I 期 / II 期招募中美国NCT06143566Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis/Acute Pancreatitis Associated Diabetes Mellitus
II 期招募中美国NCT06729996Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF
II 期招募中RussiaNCT06655480Effect of Empagliflozin on Inflammation
IV 期招募中LebanonNCT07292909The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
I 期 / II 期招募中美国NCT05972564Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II
IV 期招募中PakistanNCT06706791Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD
IV 期招募中美国NCT06110130Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes
IV 期招募中SloveniaNCT06613854The Efficacy of Empagliflozin on Kidney Functions in Lupus Nephritis Population
IV 期招募中EgyptNCT07700940A Study in Healthy People to Compare How 2 Different Formulations of Vicadrostat / Empagliflozin Tablets Are Taken up in the Body
I 期招募中德国NCT07845630Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE Prevention
III 期招募中法国德国意大利瑞士NCT06653738SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia
I 期招募中美国NCT07053306A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension
I 期招募中中国NCT06554301Improving Coronary Vascular Health in Women
II 期招募中美国NCT06843902Randomized Trial of SGLT2i in Heart Transplant Recipients
IV 期招募中美国NCT06625073Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes
早期 I 期招募中美国NCT06609356SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan
早期 I 期招募中美国NCT05057806SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial
II 期招募中美国NCT05138575Empagliflozin Treatment in Kidney Transplant Recipients
IV 期招募中美国NCT06013865The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination
不适用招募中GreeceNCT03878706Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes
不适用招募中瑞典NCT05501483Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study
IV 期招募中South KoreaNCT07572032A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
III 期招募中美国Brazil加拿大中国NCT06024746
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。